Researchers identify biomarkers for infliximab response in pediatric patients with CD

Researchers identify biomarkers for infliximab response in pediatric patients with CD

Researchers identified novel candidate biomarkers for infliximab response after unsupervised plasma proteomic analysis in pediatric patients with Crohn’s disease, according to a presentation at Digestive Disease Week.“For pediatric inflammatory bowel disease, precision medicine is selecting the right drug for the right patient and providing the right dose at the right time. … As you know, the anti-TNFs are the only FDA approved biologic for pediatric IBD; the clinical response rate is high, yet the rates of endoscopic and deep remission are low,” Phillip Minar, MD, MS,Read More

Share on facebook
Share on twitter
Share on linkedin